The alternative complement pathway regulates pathological angiogenesis in the retina

FASEB Journal

Volumn 28, Issue 7, 2014, Pages 3171-3182

  Sweigard, J Harry ^a   Yanai, Ryoji ^a   Gaissert, Philipp ^a   Saint Geniez, Magali ^b   Kataoka, Keiko ^a   Thanos, Aristomenis ^a   Stahl, Gregory L ^c   Lambris, John D ^d   Connor, Kip M ^a  

^a Angiogenesis Laboratory   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cd55; Factor b; Innate immune system; Neovascularization; Oxygen induced retinopathy

Indexed keywords

DECAY ACCELERATING FACTOR; OXYGEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; LASER CAPTURE MICRODISSECTION; MICROENVIRONMENT; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

CD55; FACTOR B; INNATE IMMUNE SYSTEM; NEOVASCULARIZATION; OXYGEN-INDUCED RETINOPATHY;

ANIMALS; ANTIGENS, CD55; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; RETINA; RETINAL DISEASES; RETINAL NEOVASCULARIZATION;

EID: 84903713976     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-251041     Document Type: Article

References (50)

1. Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (Pubitemid 46505878)
2. Moulton, K. S. (2006) Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr. Opin. Lipidol. 17, 548-555 (Pubitemid 44372686)
3. Stahl, A., Connor, K. M., Sapieha, P., Chen, J., Dennison, R. J., Krah, N. M., Seaward, M. R., Willett, K. L., Aderman, C. M., Guerin, K. I., Hua, J., Lofqvist, C., Hellstrom, A., and Smith, L. E. (2010) The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 51, 2813-2826
4. Stem, M. S., and Gardner, T. W. (2013) Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr. Med. Chem. 20, 3241-3250
5. Chen, J., and Smith, L. E. (2007) Retinopathy of prematurity. Angiogenesis 10, 133-140 (Pubitemid 46440629)
6. Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., and Hartnett, M. E. (2008) Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 27, 331-371
7. Connor, K. M., SanGiovanni, J. P., Lofqvist, C., Aderman, C. M., Chen, J., Higuchi, A., Hong, S., Pravda, E. A., Majchrzak, S., Carper, D., Hellstrom, A., Kang, J. X., Chew, E. Y., Salem, N., Jr., Serhan, C. N., and Smith, L. E. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873 (Pubitemid 47038185)
8. Gardiner, T. A., Gibson, D. S., de Gooyer, T. E., de la Cruz, V. F., McDonald, D. M., and Stitt, A. W. (2005) Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopa-thy. Am. J. Pathol. 166, 637-644 (Pubitemid 40189058)
9. Connor, K. M., Krah, N. M., Dennison, R. J., Aderman, C. M., Chen, J., Guerin, K. I., Sapieha, P., Stahl, A., Willett, K. L., and Smith, L. E. (2009) Quantification of oxygen-induced retinop-athy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protocols 4, 1565-1573
10. Mechoulam, H., and Pierce, E. A. (2003) Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am J. Pharmacogenomics 3, 261-277 (Pubitemid 37075632)
11. Adamis, A. P., and Berman, A. J. (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 30, 65-84
12. Langer, H. F., Chung, K. J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., DeAngelis, R. A., Roche, P. A., Magotti, P., Li, X., Economopoulou, M., Rafail, S., Lambris, J. D., and Chavakis, T. (2010) Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116, 4395-4403
13. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797
14. Ricklin, D., and Lambris, J. D. (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831-3838
15. Nilsson, B., and Nilsson Ekdahl, K. (2012) The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217, 1106-1110
16. Forneris, F., Ricklin, D., Wu, J., Tzekou, A., Wallace, R. S., Lambris, J. D., and Gros, P. (2010) Structures of C3b in complex with factors B and D give insight into complement conver-tase formation. Science 330, 1816-1820
17. Kemper, C., Leung, M., Stephensen, C. B., Pinkert, C. A., Liszewski, M. K., Cattaneo, R., and Atkinson, J. P. (2001) Membrane cofactor protein (MCP; CD46) expression in trans-genic mice. Clin. Exp. Immunol. 124, 180-189 (Pubitemid 32587601)
18. Harris, C. L., Rushmere, N. K., and Morgan, B. P. (1999) Molecular and functional analysis of mouse decay accelerating factor (Cd55). Biochem. J. 341, 821-829 (Pubitemid 29389216)
19. Hamilton, K. K., Ji, Z., Rollins, S., Stewart, B. H., and Sims, P. J. (1990) Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 76, 2572-2577
20. Rollins, S. A., and Sims, P. J. (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144, 3478-3483 (Pubitemid 20146382)
21. Hourcade, D., Liszewski, M. K., Krych-Goldberg, M., and Atkinson, J. P. (2000) Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharma-cology 49, 103-116 (Pubitemid 30445222)
22. Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., O'Brien-Jenkins, A., Randall, T. C., Rubin, S. C., and Coukos, G. (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 63, 3403-3412 (Pubitemid 36735901)
23. Morita, M., Ohneda, O., Yamashita, T., Takahashi, S., Suzuki, N., Nakajima, O., Kawauchi, S., Ema, M., Shibahara, S., Udono, T., Tomita, K., Tamai, M., Sogawa, K., Yamamoto, M., and Fujii-Kuriyama, Y. (2003) HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134-1146 (Pubitemid 36313597)
24. Weidemann, A., Krohne, T. U., Aguilar, E., Kurihara, T., Takeda, N., Dorrell, M. I., Simon, M. C., Haase, V. H., Friedlander, M., and Johnson, R. S. (2010) Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 58, 1177-1185
25. Sasidharan, C. K., Kumar, M. S., Anoop, P., Syamala, B., and Das, B. N. (2003) Spontaneous regression of retinopathy of prematurity. Indian J. Pediatr. 70, 359-360 (Pubitemid 36612580)
26. Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P., and Smith, L. E. (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovas-cularization. Proc. Natl. Acad. Sci. U.S.A. 92, 905-909
27. Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., and Smith, L. E. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461
28. Ozaki, H., Seo, M. S., Ozaki, K., Yamada, H., Yamada, E., Okamoto, N., Hofmann, F., Wood, J. M., and Campochiaro, P. A. (2000) Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156, 697-707 (Pubitemid 30643824)
29. Saishin, Y., Takahashi, K., Lima e Silva, R., Hylton, D., Rudge, J. S., Wiegand, S. J., and Campochiaro, P. A. (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195, 241-248 (Pubitemid 36384298)
30. Seo, M. S., Kwak, N., Ozaki, H., Yamada, H., Okamoto, N., Yamada, E., Fabbro, D., Hofmann, F., Wood, J. M., and Campo-chiaro, P. A. (1999) Dramatic inhibition of retinal and choroi-dal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. 154, 1743-1753 (Pubitemid 29262856)
31. Pierce, E. A., Foley, E. D., and Smith, L. E. (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 114, 1219-1228 (Pubitemid 26338853)
32. Rus, H., Cudrici, C., David, S., and Niculescu, F. (2006) The complement system in central nervous system diseases. Autoim-munity 39, 395-402 (Pubitemid 44269617)
33. Hoang, M. V., Smith, L. E., and Senger, D. R. (2011) Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. Biochim. Biophys. Acta 1812, 549-557
34. Hoang, M. V., Smith, L. E., and Senger, D. R. (2010) Moderate GSK-3beta inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis 13, 269-277
35. Okroj, M., Corrales, L., Stokowska, A., Pio, R., and Blom, A. M. (2009) Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol. Immunother. 58, 1771-1780
36. Pedersen, E. D., Froyland, E., Kvissel, A. K., Pharo, A. M., Skalhegg, B. S., Rootwelt, T., and Mollnes, T. E. (2007) Expression of complement regulators and receptors on human NT2-N neurons-effect of hypoxia and reoxygenation. Mol. Immunol. 44, 2459-2468 (Pubitemid 46097099)
37. Suzuki, H., Lasbury, M. E., Fan, L., Vittal, R., Mickler, E. A., Benson, H. L., Shilling, R., Wu, Q., Weber, D. J., Wagner, S. R., Lasaro, M., Devore, D., Wang, Y., Sandusky, G. E., Lipking, K., Pandya, P., Reynolds, J., Love, R., Wozniak, T., Gu, H., Brown, K. M., and Wilkes, D. S. (2013) Role of complement activation in obliterative bronchiolitis post-lung transplantation. J. Immunol. 191, 4431-4439
38. Zimmermann, A., Gerber, H., Nussenzweig, V., and Isliker, H. (1990) Decay-accelerating factor in the cardiomyocytes of normal individuals and patients with myocardial infarction. Virch. Arch. A Pathol. Anat. Histopathol. 417, 299-304 (Pubitemid 20317451)
39. Vakeva, A., and Meri, S. (1998) Complement activation and regulator expression after anoxic injury of human endothe-lial cells. APMIS 106, 1149-1156 (Pubitemid 29075899)
40. Harris, C. L., Pettigrew, D. M., Lea, S. M., and Morgan, B. P. (2007) Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay. J. Immunol. 178, 352-359 (Pubitemid 46039662)
41. Yanai, R., Thanos, A., and Connor, K. M. (2012) Complement involvement in neovascular ocular diseases. Adv. Exp. Med Biol. 946, 161-183
42. Roumenina, L. T., Loirat, C., Dragon-Durey, M. A., Halbwachs-Mecarelli, L., Sautes-Fridman, C., and Fremeaux-Bacchi, V. (2011) Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365, 8-26
43. Van der Schoot, C. E., Huizinga, T. W., van 't Veer-Korthof, E. T., Wijmans, R., Pinkster, J., and von dem Borne, A. E. (1990) Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglo-binuria, description of a new diagnostic cytofluorometric assay. Blood 76, 1853-1859
44. Walport, M. J. (2001) Complement: first of two parts. N. Engl. J. Med. 344, 1058-1066
45. Walport, M. J. (2001) Complement: second of two parts. N. Engl. J. Med. 344, 1140-1144
46. Nauta, A. J., Daha, M. R., Tijsma, O., van de Water, B., Tedesco, F., and Roos, A. (2002) The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 32, 783-792 (Pubitemid 34257556)
47. Kim, D. D., and Song, W. C. (2006) Membrane complement regulatory proteins. Clin. Immunol. 118, 127-136 (Pubitemid 43199649)
48. Ramaglia, V., King, R. H., Morgan, B. P., and Baas, F. (2009) Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol. Immunol. 46, 1892-1896
49. Song, W. C. (2004) Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr. Dir. Autoimmun. 7, 181-199
50. Brodsky, S. V., Nadasdy, G. M., Pelletier, R., Satoskar, A., Birmingham, D. J., Hadley, G. A., Obeidat, K., and Nadasdy, T. (2009) Expression of the decay-accelerating factor (Cd55) in renal transplants: a possible prediction marker of allograft survival. Transplantation 88, 457-464